Developer docs
API playgroundTry for free, no card

Search company profiles

TandemAI

Full company profile

uuid0000hwq

Namestring
TandemAI
Legal namestring
TandemAI US, LLC / TandemAI Suzhou Co., Ltd.
Websiteurl
tandemai.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

TandemAI is a privately held drug discovery technology company founded in 2021 that operates an integrated AI- and physics-based computational platform combined with wet lab experimentation capabilities. Its core product is TandemViz, a cloud-based browser workspace that unifies proprietary computational modules — including TandemFEP (free energy perturbation with quantum-mechanics-derived force fields), TandemGen (generative AI for molecular ideation), TandemADMET (ML-based ADMET prediction), TandemDynamics, TandemDock, TandemAnalytics, TandemSandbox, and a QuickCycle integrated dry-wet workflow — with tools for tracking synthesis (TandemQueue) and managing experimental data. The platform supports hit identification, hit-to-lead and lead optimization, scaffold hopping, ADMET prediction, and virtual screening, and has been used to deliver a development candidate in under 18 months for partners including Perpetual Medicines and Third Rock Ventures.

The company monetizes through two primary models: FTE-based service contracts that bundle wet lab services (medicinal chemistry, synthetic chemistry, biological assays, structural biology) with complimentary access to TandemViz computational tools, and standalone SaaS software licensing of the TandemViz platform with optional GPU services and virtual private cloud deployment. Its go-to-market is direct enterprise sales targeting biopharmaceutical and biotech firms in the US and China, supplemented by academic and biotech partnerships, industry symposia (Boston, Cambridge), webinars, and content marketing.

TandemAI is headquartered in New York with operations in Cambridge (Massachusetts), Suzhou, and Shanghai, employing over 350 professionals including 50+ AI and computational chemistry scientists and 200+ synthetic chemists. The company has raised over $80M across a $25M seed/pre-Series A (December 2021, OrbiMed and Chengwei Capital), $35M Series A (October 2023, Qiming Venture Partners), and $22M Series A extension (November 2025, V-Capital and KHK Fund). In July 2025, TandemAI merged with Perpetual Medicines to extend the platform into peptide therapeutics, and in May 2026 partnered with Mila to apply world models to drug discovery simulation. The company serves over 150 biopharmaceutical clients globally, with reported quantitative outcomes including at least 50% reduction in hit-to-lead and lead optimization timelines and a 5x expansion of design space.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
computational drug discovery, AI drug discovery platform, medicinal chemistry services, generative molecular design, free energy perturbation
Industry1 code
PRIMARYHDAGAEAB
Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand)
Hardware, Technology & Telecom/Quantum Computing/Quantum Simulation & Digital Twins
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Software Publishers5132
  • Computer Systems Design and Related Services54151
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Prepackaged Software7372
Product category
AI Drug Discovery Platform
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1FTE-Based Service Contracts
TypeProfessional Services
Description

Full-Time Equivalent (FTE) pricing model where clients pay for wet lab services and receive complimentary access to TandemAI's proprietary computational and AI tools. Includes medicinal chemistry, synthetic chemistry, biological assays, and computational drug discovery services. Flexible engagement modes include traditional FTE, flexible FTE, and fee-for-service (FFS).

tandemai.com
2SaaS Software Licensing
TypeSubscription Recurring
Description

Stand-alone software license (SaaS) model providing access to TandemViz platform and all its computational modules including TandemFEP, TandemGen, TandemADMET, TandemDock, TandemDynamics, TandemAnalytics, and TandemSandbox. Optional GPU services and virtual private cloud (VPC) deployment available.

tandemai.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Pricing details2 tiers
1FTE-Based Wet Lab + Computational Tools
ModelHybridBilling cadenceMulti-year contract
Notes

Wet lab services (medicinal chemistry, synthetic chemistry, biological assays) billed on FTE basis with complimentary access to all TandemViz computational tools. Flexible FTE mode available based on actual workloads. Fee-for-service (FFS) option for specific assays or projects.

tandemai.com
2SaaS Standalone Software License
ModelSubscriptionBilling cadenceAnnual
Notes

Standalone SaaS license giving access to all TandemViz modules. Optional GPU services and VPC deployment available. Pricing not publicly disclosed; quote-based.

tandemai.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 10 records shown
1TandemViz
Description

Next-generation cloud-enabled discovery platform that integrates access to physics-based and AI in-silico drug design software with tools to manage and analyze wet lab results.

tandemai.com
+9 more records
Core offering1 text field

TandemAI provides an integrated drug discovery platform combining physics-based computational methods (FEP, molecular dynamics) and generative AI molecular design with large-scale wet lab experimentation. The core software product is TandemViz, a cloud-based browser workspace integrating computational modules (TandemFEP, TandemGen, TandemADMET, TandemDock, TandemDynamics, TandemAnalytics, TandemSandbox) with wet lab workflow management. The offering is delivered either as FTE-based CRO services bundling wet lab work with complimentary computational tool access, or as standalone SaaS licensing of the TandemViz platform with optional GPU services and VPC deployment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Hit-to-lead and lead optimization timelines reduced by at least 50%
+5 more records
Product overview1 text field

TandemAI is an integrated drug discovery technology company offering a cloud-based platform called TandemViz that combines AI-driven and physics-based computational methods with wet lab experimentation capabilities. The platform architecture consists of TandemViz as the core unified workspace integrating multiple computational modules (TandemFEP for binding affinity calculations, TandemGen for generative AI molecular design, TandemADMET for ADMET prediction, TandemDynamics for molecular simulations, TandemDock for molecular docking, TandemAnalytics for structure-activity analysis, TandemSandbox for structural modeling, TandemFilters for molecule filtering, TandemQueue for synthesis tracking, TandemVault for data management, TandemScreen for virtual screening) with wet lab services including medicinal chemistry, biological assays, and a dedicated peptide platform. Available via FTE service pricing or SaaS software license with optional GPU services and VPC deployment.

Product and service7 records
1TandemViz
CategoryDrug Discovery Software Platform
Description

Cloud-based drug discovery platform integrating physics-based and AI computational tools with wet lab data management, enabling collaboration across computational and experimental workflows for biopharma and biotech customers.

2Medicinal Chemistry & Synthesis Service
CategoryDrug Discovery CRO Services
Description

Synthetic and medicinal chemistry services including synthesis from milligrams to kilograms, with capabilities in PROTACs, molecular glues, and conjugated drugs, performed by a 200+ chemist team.

3Biological Assays Service
CategoryDrug Discovery CRO Services
Description

Comprehensive biological services including protein production, biochemical assays, cell-based assays, biophysical assays, and structural biology via X-ray crystallography for biopharma discovery programs.

4Hit Identification Service
CategoryDrug Discovery CRO Services
Description

Comprehensive hit finding using virtual screening, pharmacophore screening, fragment screening, and DEL screening approaches, powered by the TandemScreen virtual screening platform.

5Hit-to-Lead and Lead Optimization Service
CategoryDrug Discovery CRO Services
Description

Computational tools and wet lab services for multi-parameter optimization of potency, selectivity, and pharmacokinetic properties during hit-to-lead and lead optimization phases.

6Peptide Platform
CategoryDrug Discovery Platform
Description

AI computational design platform for peptide therapeutics with automated synthesis capabilities, covering oncology, metabolic, and autoimmune disease targets.

7Digital Assays & Workflows
CategoryDrug Discovery CRO Services
Description

In silico assays including binding affinity predictions, ADMET predictions, virtual HTS, and QuickCycle workflow for reducing drug discovery timelines, available as part of the integrated service offering.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-10
Description

Third Rock Ventures partnered with Perpetual Medicines (now part of TandemAI following the 2025 merger) to deliver a development candidate in under 18 months using TandemAI's computational physics and AI-driven platform. The partnership paired Perpetual Medicines' specialized drug hunting and design capabilities with Third Rock Ventures' strategic and therapeutic expertise. The successful outcome establishes a blueprint for venture capital and cutting-edge computational platform collaboration.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-23
Description

Mila, the Quebec Artificial Intelligence Institute, partnered with TandemAI to apply world models—machine learning frameworks traditionally used in video games and autonomous vehicles—to accelerate drug discovery. The collaboration leverages Mila's deep learning expertise and TandemAI's TandemViz platform to simulate complex chemical interactions with greater accuracy. Both organizations are committed to open science and responsible AI development, emphasizing knowledge sharing and accessibility within the scientific community.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-07-10
Description

Perpetual Medicines and TandemAI announced a strategic merger in July 2025 to expand physics and AI-based drug discovery capabilities. Perpetual Medicines leverages TandemAI's integrated platform, and the merger created an expanded integrated AI-enabled small molecule and peptide discovery platform. Perpetual Medicines used the combined platform to deliver a development candidate for Third Rock Ventures in under 18 months.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public computational drug discovery company combining physics-based methods (FEP+, Glide) with a SaaS platform and collaborative drug discovery services. Most directly comparable to TandemAI's physics-and-AI plus integrated platform model, with overlapping customers in biopharma R&D.

TypeDirect peer
Description

AI-driven small molecule discovery company using structure-based deep learning for hit identification and optimization. Comparable to TandemAI's virtual screening, generative design, and pharma/biotech partnership model.

TypeDirect peer
Description

China-headquartered AI and quantum physics-based drug discovery company offering integrated computational chemistry plus wet lab services. Closest geographic and product-model peer to TandemAI, with similar FTE plus SaaS GTM to global biopharma.

TypeDirect peer
Description

AI-driven drug discovery company with end-to-end platform spanning target identification, generative chemistry, and internal pipeline assets. Comparable to TandemAI's full-stack AI/physics approach and its evolution toward asset creation through partnerships and internal programs.

TypeDirect peer
Description

Public AI drug discovery company combining high-throughput wet lab biology with machine learning for target and molecule discovery. Comparable to TandemAI on the thesis that integrated dry/wet lab plus AI is the winning model for preclinical R&D.

TypeDirect peer
Description

Machine learning-driven drug discovery company partnering with pharma (e.g., Lilly, BMS) on target ID and chemistry. Comparable to TandemAI's enterprise pharma partnership model, though Insitro is more biology/genomics-led while TandemAI emphasizes chemistry and physics.

7Isomorphic Labs
TypeDirect peer
Description

Alphabet-owned AI drug discovery company applying DeepMind's protein structure prediction (AlphaFold) and generative chemistry to pharma collaborations. A well-capitalized direct competitor in AI-driven molecular design with major pharma partnerships.

8Iambic Therapeutics
TypeEmerging player
Description

AI-driven drug discovery company combining physics-based and machine-learning models for small molecule design, with an internal pipeline. Comparable emerging-stage peer focused on generative chemistry and physics-informed modeling.

TypeEmerging player
Description

AI protein design and engineering company serving biotech and pharma R&D teams via a SaaS-style platform. Adjacent emerging peer using generative AI to expand design space, conceptually similar to TandemGen and virtual screening capabilities.

TypeBroad incumbent
Description

Large public CRO providing integrated drug discovery and preclinical services, including computational chemistry and medicinal chemistry. Broad incumbent offering overlapping wet-lab discovery services, but as part of a much wider portfolio rather than a specialized AI/physics platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature16 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TandemAI

AI Drug Discovery Platformtandemai.com

What TandemAI does

TandemAI is a privately held drug discovery technology company founded in 2021 that operates an integrated AI- and physics-based computational platform combined with wet lab experimentation capabilities. Its core product is TandemViz, a cloud-based browser workspace that unifies proprietary computational modules — including TandemFEP (free energy perturbation with quantum-mechanics-derived force fields), TandemGen (generative AI for molecular ideation), TandemADMET (ML-based ADMET prediction), TandemDynamics, TandemDock, TandemAnalytics, TandemSandbox, and a QuickCycle integrated dry-wet workflow — with tools for tracking synthesis (TandemQueue) and managing experimental data. The platform supports hit identification, hit-to-lead and lead optimization, scaffold hopping, ADMET prediction, and virtual screening, and has been used to deliver a development candidate in under 18 months for partners including Perpetual Medicines and Third Rock Ventures.

The company monetizes through two primary models: FTE-based service contracts that bundle wet lab services (medicinal chemistry, synthetic chemistry, biological assays, structural biology) with complimentary access to TandemViz computational tools, and standalone SaaS software licensing of the TandemViz platform with optional GPU services and virtual private cloud deployment. Its go-to-market is direct enterprise sales targeting biopharmaceutical and biotech firms in the US and China, supplemented by academic and biotech partnerships, industry symposia (Boston, Cambridge), webinars, and content marketing.

TandemAI is headquartered in New York with operations in Cambridge (Massachusetts), Suzhou, and Shanghai, employing over 350 professionals including 50+ AI and computational chemistry scientists and 200+ synthetic chemists. The company has raised over $80M across a $25M seed/pre-Series A (December 2021, OrbiMed and Chengwei Capital), $35M Series A (October 2023, Qiming Venture Partners), and $22M Series A extension (November 2025, V-Capital and KHK Fund). In July 2025, TandemAI merged with Perpetual Medicines to extend the platform into peptide therapeutics, and in May 2026 partnered with Mila to apply world models to drug discovery simulation. The company serves over 150 biopharmaceutical clients globally, with reported quantitative outcomes including at least 50% reduction in hit-to-lead and lead optimization timelines and a 5x expansion of design space.

TandemAI firmographics

Firmographics
Name
TandemAI
Legal name
TandemAI US, LLC / TandemAI Suzhou Co., Ltd.
Website
https://tandemai.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

TandemAI industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Scientific Research and Development Services (5417), Software Publishers (5132), Computer Systems Design and Related Services (54151)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHDAGAEAB
Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand)
Hardware, Technology & Telecom/Quantum Computing/Quantum Simulation & Digital Twins

Keywords

  • Computational drug discovery
  • AI drug discovery platform
  • Medicinal chemistry services
  • Generative molecular design
  • Free energy perturbation

Where TandemAI is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices4 records

Markets served

TandemAI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. FTE-Based Service Contracts: Full-Time Equivalent (FTE) pricing model where clients pay for wet lab services and receive complimentary access to TandemAI's proprietary computational and AI tools. Includes medicinal chemistry, synthetic chemistry, biological assays, and computational drug discovery services. Flexible engagement modes include traditional FTE, flexible FTE, and fee-for-service (FFS).
  2. SaaS Software Licensing: Stand-alone software license (SaaS) model providing access to TandemViz platform and all its computational modules including TandemFEP, TandemGen, TandemADMET, TandemDock, TandemDynamics, TandemAnalytics, and TandemSandbox. Optional GPU services and virtual private cloud (VPC) deployment available.

Pricing tiers

ModelBillingPrice
HybridMulti-year contractFTE-Based Wet Lab + Computational Tools
SubscriptionAnnualSaaS Standalone Software License

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

TandemAI product offering

Product offering

Core offering

TandemAI provides an integrated drug discovery platform combining physics-based computational methods (FEP, molecular dynamics) and generative AI molecular design with large-scale wet lab experimentation. The core software product is TandemViz, a cloud-based browser workspace integrating computational modules (TandemFEP, TandemGen, TandemADMET, TandemDock, TandemDynamics, TandemAnalytics, TandemSandbox) with wet lab workflow management. The offering is delivered either as FTE-based CRO services bundling wet lab work with complimentary computational tool access, or as standalone SaaS licensing of the TandemViz platform with optional GPU services and VPC deployment.

Product overview

TandemAI is an integrated drug discovery technology company offering a cloud-based platform called TandemViz that combines AI-driven and physics-based computational methods with wet lab experimentation capabilities. The platform architecture consists of TandemViz as the core unified workspace integrating multiple computational modules (TandemFEP for binding affinity calculations, TandemGen for generative AI molecular design, TandemADMET for ADMET prediction, TandemDynamics for molecular simulations, TandemDock for molecular docking, TandemAnalytics for structure-activity analysis, TandemSandbox for structural modeling, TandemFilters for molecule filtering, TandemQueue for synthesis tracking, TandemVault for data management, TandemScreen for virtual screening) with wet lab services including medicinal chemistry, biological assays, and a dedicated peptide platform. Available via FTE service pricing or SaaS software license with optional GPU services and VPC deployment.

Differentiator

Problem solved

Functional benefit

Brands

  • TandemViz: Next-generation cloud-enabled discovery platform that integrates access to physics-based and AI in-silico drug design software with tools to manage and analyze wet lab results.
  • TandemFEP
  • TandemGen
  • TandemADMET
  • TandemDock
  • TandemDynamics
  • TandemAnalytics
  • TandemSandbox
  • QuickCycle
  • CoreHop-FEP / CBFE

Products and services

  • TandemViz Cloud-based drug discovery platform integrating physics-based and AI computational tools with wet lab data management, enabling collaboration across computational and experimental workflows for biopharma and biotech customers.
  • Medicinal Chemistry & Synthesis Service Synthetic and medicinal chemistry services including synthesis from milligrams to kilograms, with capabilities in PROTACs, molecular glues, and conjugated drugs, performed by a 200+ chemist team.
  • Biological Assays Service Comprehensive biological services including protein production, biochemical assays, cell-based assays, biophysical assays, and structural biology via X-ray crystallography for biopharma discovery programs.
  • Hit Identification Service Comprehensive hit finding using virtual screening, pharmacophore screening, fragment screening, and DEL screening approaches, powered by the TandemScreen virtual screening platform.
  • Hit-to-Lead and Lead Optimization Service Computational tools and wet lab services for multi-parameter optimization of potency, selectivity, and pharmacokinetic properties during hit-to-lead and lead optimization phases.
  • Peptide Platform AI computational design platform for peptide therapeutics with automated synthesis capabilities, covering oncology, metabolic, and autoimmune disease targets.
  • Digital Assays & Workflows In silico assays including binding affinity predictions, ADMET predictions, virtual HTS, and QuickCycle workflow for reducing drug discovery timelines, available as part of the integrated service offering.

Quantifiable outcome

  • Hit-to-lead and lead optimization timelines reduced by at least 50%
  • +5 more outcomes

Companies that use TandemAI

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

TandemAI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature16 records

TandemAI partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship.

  • Third Rock VenturesflagshipStrategic or Co-development Partner · 10 June 2026Third Rock Ventures partnered with Perpetual Medicines (now part of TandemAI following the 2025 merger) to deliver a development candidate in under 18 months using TandemAI's computational physics and AI-driven platform. The partnership paired Perpetual Medicines' specialized drug hunting and design capabilities with Third Rock Ventures' strategic and therapeutic expertise. The successful outcome establishes a blueprint for venture capital and cutting-edge computational platform collaboration.
  • Mila (Quebec Artificial Intelligence Institute)flagshipStrategic or Co-development Partner · 23 May 2026Mila, the Quebec Artificial Intelligence Institute, partnered with TandemAI to apply world models—machine learning frameworks traditionally used in video games and autonomous vehicles—to accelerate drug discovery. The collaboration leverages Mila's deep learning expertise and TandemAI's TandemViz platform to simulate complex chemical interactions with greater accuracy. Both organizations are committed to open science and responsible AI development, emphasizing knowledge sharing and accessibility within the scientific community.
  • Perpetual MedicinesflagshipStrategic or Co-development Partner · 10 July 2025Perpetual Medicines and TandemAI announced a strategic merger in July 2025 to expand physics and AI-based drug discovery capabilities. Perpetual Medicines leverages TandemAI's integrated platform, and the merger created an expanded integrated AI-enabled small molecule and peptide discovery platform. Perpetual Medicines used the combined platform to deliver a development candidate for Third Rock Ventures in under 18 months.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

TandemAI competitors and assessment

Company assessment

Direct peers

  • Schrödinger: Public computational drug discovery company combining physics-based methods (FEP+, Glide) with a SaaS platform and collaborative drug discovery services. Most directly comparable to TandemAI's physics-and-AI plus integrated platform model, with overlapping customers in biopharma R&D.
  • Atomwise: AI-driven small molecule discovery company using structure-based deep learning for hit identification and optimization. Comparable to TandemAI's virtual screening, generative design, and pharma/biotech partnership model.
  • XtalPi: China-headquartered AI and quantum physics-based drug discovery company offering integrated computational chemistry plus wet lab services. Closest geographic and product-model peer to TandemAI, with similar FTE plus SaaS GTM to global biopharma.
  • Insilico Medicine: AI-driven drug discovery company with end-to-end platform spanning target identification, generative chemistry, and internal pipeline assets. Comparable to TandemAI's full-stack AI/physics approach and its evolution toward asset creation through partnerships and internal programs.
  • Recursion Pharmaceuticals: Public AI drug discovery company combining high-throughput wet lab biology with machine learning for target and molecule discovery. Comparable to TandemAI on the thesis that integrated dry/wet lab plus AI is the winning model for preclinical R&D.
  • Insitro: Machine learning-driven drug discovery company partnering with pharma (e.g., Lilly, BMS) on target ID and chemistry. Comparable to TandemAI's enterprise pharma partnership model, though Insitro is more biology/genomics-led while TandemAI emphasizes chemistry and physics.
  • Isomorphic Labs: Alphabet-owned AI drug discovery company applying DeepMind's protein structure prediction (AlphaFold) and generative chemistry to pharma collaborations. A well-capitalized direct competitor in AI-driven molecular design with major pharma partnerships.

Emerging players

  • Iambic Therapeutics: AI-driven drug discovery company combining physics-based and machine-learning models for small molecule design, with an internal pipeline. Comparable emerging-stage peer focused on generative chemistry and physics-informed modeling.
  • Cradle Bio: AI protein design and engineering company serving biotech and pharma R&D teams via a SaaS-style platform. Adjacent emerging peer using generative AI to expand design space, conceptually similar to TandemGen and virtual screening capabilities.

Broad incumbents

  • Charles River Laboratories: Large public CRO providing integrated drug discovery and preclinical services, including computational chemistry and medicinal chemistry. Broad incumbent offering overlapping wet-lab discovery services, but as part of a much wider portfolio rather than a specialized AI/physics platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

TandemAI social profiles

Digital presence

TandemAI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TandemAI leadership team

Management profile

Number of profiles

Profiles6 records

TandemAI funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TandemAI M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TandemAI

What does TandemAI do?

TandemAI provides an integrated drug discovery platform combining physics-based computational methods (FEP, molecular dynamics) and generative AI molecular design with large-scale wet lab experimentation. The core software product is TandemViz, a cloud-based browser workspace integrating computational modules (TandemFEP, TandemGen, TandemADMET, TandemDock, TandemDynamics, TandemAnalytics, TandemSandbox) with wet lab workflow management. The offering is delivered either as FTE-based CRO services bundling wet lab work with complimentary computational tool access, or as standalone SaaS licensing of the TandemViz platform with optional GPU services and VPC deployment.

Is TandemAI a public or private company?

TandemAI is a private company. It is classified as venture growth investor backed and is currently operating.

When was TandemAI founded?

TandemAI was founded in 2021. It employs 51 to 100 people.

Where is TandemAI based?

TandemAI is headquartered in New York, United States, in the North America region.

How does TandemAI make money?

Two revenue lines are on record. FTE-Based Service Contracts are the primary driver. The others are saaS Software Licensing.

Who are TandemAI's main competitors?

Direct peers on record are Schrödinger, Atomwise, XtalPi, Insilico Medicine, Recursion Pharmaceuticals, Insitro and Isomorphic Labs. Emerging players are Iambic Therapeutics and Cradle Bio. Charles River Laboratories is listed as a broad incumbent.

Does TandemAI have an API?

No public API is recorded for TandemAI.

What industry is TandemAI in?

TandemAI's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HDAGAEAB, Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PedailyThe semi-invasive vagus nerve stimulation device development company 'Aikailingshu' has completed tens of millions in angel round financing.Aikailingshu, a vagus nerve modulation device developer, completed an angel round led by Shicui Capital. The funds will support production facilities and clinical registration of its first Class III device. The company targets official approval by end of 2027.Pedaily"Niu Lun Jie Bio" completes nearly 100 million yuan Series A financing, laying out the neuron regeneration track.Nulunji Bio completed a Series A financing led by Wuhan Optics Valley Science and Technology Innovation Industry Investment Fund Partnership, with Zhuhai Hengqin Softbank following. The funds will advance clinical trials and preclinical R&D for its in-situ transdifferentiation technology, including NRG-103 for high-grade glioma, which is in Phase I clinical trials in China.Quantum ZeitgeistMila and TandemAI Partner on AI-Driven TherapeuticsMila, the Quebec Artificial Intelligence Institute, has partnered with TandemAI to apply world models—machine learning frameworks traditionally used in video games and autonomous vehicles—to accelerate drug discovery. The collaboration will leverage Mila's deep learning expertise and TandemAI's TandemViz platform to simulate complex chemical interactions with greater accuracy, aiming to improve medicines for patients. Both organizations are committed to open science and responsible AI development, with the partnership emphasizing knowledge sharing and accessibility within the scientific community.TipranksTandemAI Hosts AI-Driven Drug Discovery Symposium Highlighting Therapeutic DevelopmentTandemAI announced it is organizing an AI-driven drug discovery symposium scheduled for April 9 at The Royal Sonesta Boston in Cambridge, MA, featuring talks, panels, and networking with key opinion leaders in drug discovery, AI, and venture investment. The event positions TandemAI at the intersection of computational chemistry, drug discovery, and life sciences investing. The article suggests the symposium may signal efforts to deepen relationships with biopharma partners and venture backers, potentially supporting future collaboration opportunities, deal flow, and revenue-generating engagements in AI-enabled therapeutic development.TipranksTandemAI Hosts AI-Driven Drug Discovery Symposium in CambridgeTandemAI announced it is organizing a symposium titled "AI Driven Drug Discovery–Redefining the Road to the Clinic" in Cambridge, Massachusetts, scheduled for April 9 at The Royal Sonesta Boston. The event will feature talks, panel discussions, and networking with key opinion leaders in drug discovery, AI, and venture investment, focusing on how AI and computation are changing development candidate nomination. The company stated this ecosystem-building effort aims to enhance its visibility, deal flow, and partnership prospects in the AI-enabled drug discovery space.HLTHTandemAI Secures $22 Million to Advance AI-Driven Drug Discovery PlatformTandemAI, a drug discovery technology company, raised $22 million in a Series A extension round led by V-Capital and KHK Fund to advance its AI and computational physics-based models and expand laboratory operations. The company plans to use the funding to accelerate model development and broaden its technological capabilities to serve a growing client base in the multi-modality drug discovery space. The financing follows TandemAI's 2023 Series A round of $35 million and its July 2025 merger with Perpetual Medicines.FinSMEsTandemAI Closes $22M Series A Extension RoundTandemAI, a NYC-based drug discovery company, raised $22M in Series A extension funding from backers including KHK Fund and V-Capital. The company has raised over $80M since its 2021 founding and will use the funds to expand operations and R&D. It serves over 150 biopharmaceutical companies and has accelerated more than 50 drug pipelines.Fastdata极数腾迈医药TandemAI获得2200万美元A+轮融资 – Fastdata极数TandemAI, a technology company focused on drug molecule discovery, has raised $22 million in Series A+ funding. The round was led by V-Capital and KHK Fund, with participation from existing investors including Sequoia Capital and Qiming Venture Partners.TandemaiTandemAI Closes $22M Series A Extension Round to Accelerate AI-Driven Drug DiscoveryTandemAI secured a $22 million Series A extension to accelerate its AI-driven drug discovery platform and expand wet lab capabilities. The funding follows the company's strategic merger with Perpetual Medicines, which enhances its expertise in peptide and antibody-peptide conjugate discovery. Since its founding, TandemAI has raised over $80 million and partnered with four of the world’s top ten multinational pharmaceutical companies.